Company / R&D Expense
Relay Therapeutics, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$261.4M
FY2025
5-year range
$70.3M / $330.0M
FY2021-FY2025
Trend
-18.1%
vs FY2024
Sector context
#69 of 210
Health Care
What the data says
At $261M, Relay Therapeutics, Inc.'s r&d expense ranks #69 of 210 in the Health Care sector. Declined from $330M to $261M over the past 2 years.
Based on SEC 10-K filings.
$261M in FY2025 with a 5-year CAGR of +30.0%.
Declined from $330M to $261M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +37.8%
- 5-Year CAGR
- +30.0%
- 10-Year CAGR
- -
Sector benchmark
#69 of 210 in Health CareTop 33% of 210This company $261.4M Sector average $644.0M
▼
-59.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +30.0%, indicating consistent growth.
- In FY2025, r&d expense decreased 18.1% year-over-year.
- Ranks #69 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $261.4M | -18.1% |
| FY2024 | $319.1M | -3.3% |
| FY2023 | $330.0M | +230.5% |
| FY2022 | $99.9M | +42.0% |
| FY2021 | $70.3M | +0.0% |
| FY2020 | $70.3M | +0.0% |
| FY2019 | $70.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026